Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean E Sealey

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
American Journal of Hypertension|August 9, 2014
John H. Laragh, MD: clinician-scientistJean E Sealey
Hypertension (Dallas, Tex. : 1979)|July 9, 2008
It is the plasma renin activity level that counts, not stoichiometryJean E Sealey, John H Laragh
BMJ (Clinical Research Ed.)|April 18, 2013
Authors' reply to Messerli and colleaguesJohn H Laragh, Jean E Sealey
American Journal of Hypertension|September 23, 2011
The plasma renin test reveals the contribution of body sodium-volume content (V) and renin-angiotensin (R) vasoconstriction to long-term blood pressureJohn H Laragh, Jean E Sealey
Journal of Hypertension|July 14, 2025
Maintenance of blood pressure by reactive increases in plasma renin activity during salt depletion and renin-angiotensin system inhibitionJean E Sealey, Jon D Blumenfeld
American Journal of Hypertension|May 15, 2003
Relevance of the plasma renin hormonal control system that regulates blood pressure and sodium balance for correctly treating hypertension and for evaluating ALLHATJohn H Laragh, Jean E Sealey
American Journal of Hypertension|September 20, 2008
Aliskiren fails to lower blood pressure in patients who have either low PRA levels or whose PRA falls insufficiently or reactively risesJean E Sealey, John H Laragh
Clinical Chemistry|December 15, 2010
Plasma renin activity enzyme-kinetic assay: protection of Angiotensin I from bacterial degradationJean E Sealey, John H Laragh
American Journal of Hypertension|August 25, 2009
Using plasma renin (PRA) testing to design follow-up drug treatment strategies in hypertensive patients already taking antirenin system drugsJean E Sealey, John H Laragh
BMJ (Clinical Research Ed.)|March 21, 2013
Sodium depletion in patients in clinical trials may account for the increased cardiovascular risk of dual blockade of the renin-angiotensin systemJohn H Laragh, Jean E Sealey
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
American Journal of Hypertension|August 9, 2014
John H. Laragh, MD: clinician-scientistJean E Sealey
Hypertension (Dallas, Tex. : 1979)|July 9, 2008
It is the plasma renin activity level that counts, not stoichiometryJean E Sealey, John H Laragh
BMJ (Clinical Research Ed.)|April 18, 2013
Authors' reply to Messerli and colleaguesJohn H Laragh, Jean E Sealey
American Journal of Hypertension|September 23, 2011
The plasma renin test reveals the contribution of body sodium-volume content (V) and renin-angiotensin (R) vasoconstriction to long-term blood pressureJohn H Laragh, Jean E Sealey
Journal of Hypertension|July 14, 2025
Maintenance of blood pressure by reactive increases in plasma renin activity during salt depletion and renin-angiotensin system inhibitionJean E Sealey, Jon D Blumenfeld
American Journal of Hypertension|May 15, 2003
Relevance of the plasma renin hormonal control system that regulates blood pressure and sodium balance for correctly treating hypertension and for evaluating ALLHATJohn H Laragh, Jean E Sealey
American Journal of Hypertension|September 20, 2008
Aliskiren fails to lower blood pressure in patients who have either low PRA levels or whose PRA falls insufficiently or reactively risesJean E Sealey, John H Laragh
Clinical Chemistry|December 15, 2010
Plasma renin activity enzyme-kinetic assay: protection of Angiotensin I from bacterial degradationJean E Sealey, John H Laragh
American Journal of Hypertension|August 25, 2009
Using plasma renin (PRA) testing to design follow-up drug treatment strategies in hypertensive patients already taking antirenin system drugsJean E Sealey, John H Laragh
BMJ (Clinical Research Ed.)|March 21, 2013
Sodium depletion in patients in clinical trials may account for the increased cardiovascular risk of dual blockade of the renin-angiotensin systemJohn H Laragh, Jean E Sealey
Pageof 3